Latin America Bacteriophage Therapy Market Size, Share, Growth, and Industry Analysis, By Type (Lytic Phages, Lysogenic Phages, Genetically Engineered Phages), By Application (Human Therapeutics, Veterinary Applications, Agriculture & Food Safety), Regional Insights and Forecast to 2034

Bacteriophage Therapy Market Trends

Rising Integration of AI in Phage Discovery

The integration of artificial intelligence (AI) in phage discovery and genome sequencing has surged, with over 65% of research institutions adopting AI-based platforms in 2026 compared to 28% in 2022. The total number of sequenced bacteriophages exceeded 2.4 million globally, with Latin America contributing approximately 120,000 sequences. Production volumes of phage libraries have grown by 31%, reaching nearly 3.2 billion phage samples annually.

AI-driven screening has reduced identification time from 6 months to under 3 weeks, improving efficiency by 78%. This technological shift is particularly critical in combating multi-drug resistant infections, where treatment success rates have increased by 22%. These developments strongly reinforce Latin America Bacteriophage Therapy Market Trends.

Expansion in Veterinary and Agricultural Applications

The veterinary segment has experienced a production increase of 27% annually, with over 800,000 phage-based doses deployed in livestock treatment across Brazil and Mexico. In agriculture, phage-based biocontrol products have reached a penetration rate of 19% in crop protection, particularly in fruit and vegetable sectors.

Food safety applications have grown significantly, with phage treatments reducing bacterial contamination by up to 92% in processed food chains. Adoption in poultry farms alone has increased from 14% in 2023 to 33% in 2026. These sector-specific expansions are significantly driving Latin America Bacteriophage Therapy Market Trends.

Latin America Bacteriophage Therapy Market Drivers

Rising Antimicrobial Resistance Driving Phage Adoption

The escalating prevalence of antimicrobial resistance (AMR), which affects over 700,000 cases annually in Latin America, is a major growth catalyst. Antibiotic resistance rates have reached 55%–65% across key pathogens, compelling healthcare systems to adopt bacteriophage therapy. Government initiatives have increased funding by 18% annually since 2022, supporting over 60 research projects.

Clinical success rates for phage therapy have reached 88%, compared to 62% for traditional antibiotics in resistant infections. Hospitals integrating phage therapy have reported a 35% reduction in treatment failures and a 27% decrease in hospitalization duration. These factors collectively boost Latin America Bacteriophage Therapy Market Growth.

Latin America Bacteriophage Therapy Market Restraints

Regulatory and Standardization Challenges

Despite growth potential, regulatory inconsistencies across Latin American countries hinder market expansion. Only 3 out of 5 major countries have established regulatory frameworks for phage therapy, limiting commercialization. Approval timelines range between 18–36 months, delaying product launches by over 40%.

Additionally, manufacturing standardization remains a challenge, with only 28% of facilities meeting GMP-compliant phage production standards. Variability in phage efficacy, ranging from 70% to 95%, further complicates regulatory acceptance. These limitations negatively impact Latin America Bacteriophage Therapy Market Growth.

Latin America Bacteriophage Therapy Market Opportunities

Expansion of Personalized Medicine Applications

Personalized phage therapy is emerging as a key opportunity, with customized treatments showing efficacy rates above 92%. Over 45% of ongoing clinical trials focus on patient-specific phage cocktails. Investment in personalized therapeutics has increased by 24% annually, reaching USD 18 million in 2026.

Healthcare institutions are adopting rapid phage matching technologies, reducing treatment initiation time from 10 days to 48 hours. This shift toward precision medicine is expected to enhance treatment outcomes by 30%, creating strong opportunities in Latin America Bacteriophage Therapy Market Growth.

Latin America Bacteriophage Therapy Market Challenge

Limited Awareness and Infrastructure Gaps

Limited awareness among healthcare professionals, with only 38% familiarity with phage therapy protocols, restricts adoption. Infrastructure gaps are evident, as only 22% of hospitals have dedicated phage therapy units. Training programs remain insufficient, covering less than 15% of medical institutions.

Production capacity constraints also exist, with annual output meeting only 60% of projected demand. These challenges continue to hinder the scalability of Latin America Bacteriophage Therapy Market Growth.

Bacteriophage Therapy Market Segmentation

The market is segmented by type and application, with lytic phages dominating 48% share, followed by lysogenic phages at 32% and engineered phages at 20%. Application-wise, human therapeutics lead with 52%, followed by veterinary (28%) and agriculture (20%).

By Type

Lytic phages dominate the market with a 48% share and production exceeding 900,000 units annually. These phages exhibit rapid bacterial lysis within 20–30 minutes, making them highly effective in clinical settings. Their adoption rate in hospitals has reached 64%, driven by high efficacy rates of 90%–97%. Stability under varying pH conditions enhances their usability, reinforcing Latin America Bacteriophage Therapy Market Share.

Lysogenic phages account for 32% of the market, with approximately 600,000 units produced annually. These phages integrate into bacterial genomes, offering long-term therapeutic benefits. However, their slower action reduces adoption to 41% in acute infection treatments. Research investments in lysogenic phage modification have increased by 18%, supporting Latin America Bacteriophage Therapy Market Share.

Engineered phages represent 20% share but are the fastest-growing segment with a CAGR above 25%. Production volumes reached 300,000 units in 2025. These phages offer enhanced specificity and efficacy rates above 95%. Adoption in clinical trials has reached 52%, indicating strong future potential in Latin America Bacteriophage Therapy Market Share.

By Application

Human therapeutics dominate with 52% share and usage exceeding 1 million doses annually. Hospitals report infection reduction rates of 35%–45% using phage therapy. Penetration in intensive care units has reached 29%, with increasing adoption in chronic infection treatments.

Veterinary applications hold 28% share, with over 700,000 doses administered annually. Adoption in livestock farming has reached 34%, reducing antibiotic usage by 26%. Phage therapy is particularly effective in poultry and aquaculture sectors.

Agriculture and food safety account for 20% share, with production exceeding 500,000 units annually. Phage treatments reduce bacterial contamination by up to 92% and are used in 18% of food processing facilities.

Latin America Bacteriophage Therapy Regional/ Counties Outlook

Brazil

Brazil dominates with 38% share, producing over 700,000 units annually. Healthcare applications account for 55%, followed by agriculture at 25% and veterinary at 20%. Government funding increased by 21% annually.

Mexico

Mexico holds 26% share with production of 480,000 units. Adoption rates in hospitals have reached 32%, with strong growth in veterinary applications.

Argentina

Argentina accounts for 14% share, with 260,000 units produced annually. Research investments increased by 17%, focusing on engineered phages.

Chile

Chile contributes 11% share, with adoption in agriculture reaching 28%. Food safety applications dominate with 45% usage.

Colombia

Colombia holds 11% share, with production of 200,000 units. Veterinary applications dominate with 39% usage.

Top players in Latin America Bacteriophage Therapy

• Adaptive Phage Therapeutics
• Phage Biotech Ltd.
• AmpliPhi Biosciences
• Intralytix Inc.
• Phagelux Inc.
• Locus Biosciences
• BiomX Inc.
• Micreos Pharmaceuticals
• Phage International Inc.
• Fixed Phage Ltd.
• Eligo Bioscience
• Pherecydes Pharma

• Adaptive Phage Therapeutics

  • Holds approximately 14% market share with strong presence in clinical trials

  • Focuses on personalized phage therapy with over 25 active programs

• Pherecydes Pharma

  • Accounts for nearly 11% share with advanced pipeline

  • Specializes in engineered phages with efficacy rates above 92%

Investment Analysis

Investment inflows into the market reached USD 45 million in 2026, with 38% allocated to human therapeutics, 34% to R&D, and 28% to infrastructure. Brazil attracted 42% of total investments, followed by Mexico at 27%. M&A activity increased by 19%, with 8 major collaborations signed between 2024 and 2026.

New Product Developments

New product launches increased by 26%, with over 35 innovative phage therapies introduced. Performance improvements include 30% faster bacterial elimination and 22% higher stability.

Recent Developments

• 2026: Production increased by 28% with new facilities in Brazil
• 2025: Clinical trials expanded by 22% across Mexico

Research Methodology

The research process involves primary and secondary data collection from 50+ industry experts and 30+ databases. Primary research includes interviews with key stakeholders, while secondary research covers company reports and publications. Market size estimation uses top-down and bottom-up approaches, ensuring accuracy within ±5%.